PHBBF (Pharmaron Beijing Co) Total Stockholders Equity: $2,413 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHBBF Pharmaron Beijing Co Ltd PHBBF
84 GF Score
Price $1.93
GF Value $1.52
! 4 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Total Stockholders Equity?

Pharmaron Beijing Co PHBBF 84 Total Stockholders Equity is $2,413 Mil as of Jun. 2026. GuruFocus rates PHBBF with a GF Score™ of 84/100 and a GF Value™ of $1.52. The stock has 4 warning signs investors should review.

Pharmaron Beijing Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $2,413 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Pharmaron Beijing Co's Book Value per Share for the quarter that ended in Jun. 2026 was $1.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Pharmaron Beijing Co's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.43.

Pharmaron Beijing Co  (OTCPK:PHBBF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Pharmaron Beijing Co's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2412.818-0)/1837.284
=1.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Pharmaron Beijing Co's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(690.78 + 335.49) / 2412.818
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Total Stockholders Equity Related Terms

Pharmaron Beijing Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Total Stockholders Equity Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,590.32 1,513.06 1,758.61 1,870.61 2,138.82

Pharmaron Beijing Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,986.79 2,051.38 2,138.82 2,388.02 2,412.82
PHBBF
84GF Score
Pharmaron Beijing Co Ltd PHBBF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $2,413 Mil mean?
Pharmaron Beijing Co (PHBBF) has a Total Stockholders Equity of $2,413 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Total Stockholders Equity too high?
Pharmaron Beijing Co's current Total Stockholders Equity is $2,413 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Total Stockholders Equity compare to VRTX and REGN?
Pharmaron Beijing Co's Total Stockholders Equity of $2,413 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Total Stockholders Equity is $2,413 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Total Stockholders Equity of $2,413 Mil. The stock's GF Value™ is $1.52, compared to a current price of $1.93 — trading 27% above its estimated fair value. The current Total Stockholders Equity is $2,413 Mil. Pharmaron Beijing Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Total Stockholders Equity is $2,413 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of $1.93 is trading 27% above its estimated GF Value™ of $1.52.

Key valuation signals for PHBBF:

  • Total Stockholders Equity: $2,413 Mil
  • GF Value™: $1.52 vs. price of $1.93 (27% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
84GF Score

Get the complete analysis for PHBBF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.52
GF Value